Abstract
Toll-like receptors (TLRs) are a family of proteins with a key role in the innate immune system. They are specialized in the recognition of molecular patterns present in microbial components, through mechanisms not yet unraveled at atomic level. Improvement in the understanding of the molecular mechanisms that drive TLR signaling is of paramount importance to grasp key aspects of immunity, potentially leading to the design of new molecules able to modulate their functions. Toll-like receptor 4 (TLR4), along with its accessory protein myeloid differentiation factor 2 (MD-2), builds a heterodimeric complex that specifically recognizes lipopolysaccharides (LPS), which are present on the cell wall of gramnegative bacteria, activating the immune response. Some TLR4 modulators are undergoing preclinical and clinical evaluation for the treatment of sepsis, inflammatory diseases, cancer, and rheumatoid arthritis. Reported X-ray crystal structures together with molecular modeling studies, not reviewed before in the literature, have recently contributed to the elucidation of key interactions at atomic level of the binding between the TLR4/MD-2 system and different TLR4/MD-2 ligands. The purpose of this review is to summarize these reported studies which may account for the SAR rationalization of natural/ synthetic agonist/antagonist TLR4 binders and may also guide further design of novel TLR4 modulators.
Keywords: Toll-like receptor 4, Molecular recognition, Molecular modeling, X-ray crystallography, Modulation, Drug design, agonist/antagonist.
Current Topics in Medicinal Chemistry
Title:Modulation of Toll-Like Receptor 4. Insights from X-Ray Crystallography and Molecular Modeling
Volume: 14 Issue: 23
Author(s): Javier Klett, Jake Reeves, Nils Oberhauser, Lucia Perez-Regidor and Sonsoles Martin-Santamaria
Affiliation:
Keywords: Toll-like receptor 4, Molecular recognition, Molecular modeling, X-ray crystallography, Modulation, Drug design, agonist/antagonist.
Abstract: Toll-like receptors (TLRs) are a family of proteins with a key role in the innate immune system. They are specialized in the recognition of molecular patterns present in microbial components, through mechanisms not yet unraveled at atomic level. Improvement in the understanding of the molecular mechanisms that drive TLR signaling is of paramount importance to grasp key aspects of immunity, potentially leading to the design of new molecules able to modulate their functions. Toll-like receptor 4 (TLR4), along with its accessory protein myeloid differentiation factor 2 (MD-2), builds a heterodimeric complex that specifically recognizes lipopolysaccharides (LPS), which are present on the cell wall of gramnegative bacteria, activating the immune response. Some TLR4 modulators are undergoing preclinical and clinical evaluation for the treatment of sepsis, inflammatory diseases, cancer, and rheumatoid arthritis. Reported X-ray crystal structures together with molecular modeling studies, not reviewed before in the literature, have recently contributed to the elucidation of key interactions at atomic level of the binding between the TLR4/MD-2 system and different TLR4/MD-2 ligands. The purpose of this review is to summarize these reported studies which may account for the SAR rationalization of natural/ synthetic agonist/antagonist TLR4 binders and may also guide further design of novel TLR4 modulators.
Export Options
About this article
Cite this article as:
Klett Javier, Reeves Jake, Oberhauser Nils, Perez-Regidor Lucia and Martin-Santamaria Sonsoles, Modulation of Toll-Like Receptor 4. Insights from X-Ray Crystallography and Molecular Modeling, Current Topics in Medicinal Chemistry 2014; 14 (23) . https://dx.doi.org/10.2174/1568026614666141215144831
DOI https://dx.doi.org/10.2174/1568026614666141215144831 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Current Cardiology Reviews Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews Role of Azoles in Cancer Prevention and Treatment: Present and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry The Dialogue Between Endothelial Cells and Monocytes/Macrophages in Vascular Syndromes
Current Pharmaceutical Design Selenium Donors at the Junction of Inflammatory Diseases
Current Pharmaceutical Design Synthesis of Novel 8-Hydroxyquinoline Derivatives through Mannich Reaction and their Biological Evaluation as Potential Immunomodulatory Agents
Medicinal Chemistry Targeting Angiogenesis in Rheumatoid Arthritis
Current Rheumatology Reviews CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Cytokine-Directed Therapy in Asthma
Current Drug Targets - Inflammation & Allergy Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Computational Strategies for the Development of Novel Small Molecule Rheumatoid Arthritis Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Selected Herbals for Sports Injuries
The Natural Products Journal Chemokines in Rheumatic Diseases
Current Drug Targets Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases
Current Drug Safety Mediterranean Food Pattern in Rheumatoid Arthritis
Current Rheumatology Reviews Editorial [Hot Topic: Modulation and New Mediators in Inflammation Executive (Guest Editor: Frank A. Redegeld)]
Current Pharmaceutical Design Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Neuropathic Pain: Is the End of Suffering Starting in the Gene Therapy?
Current Drug Targets